Published on: April 2026
OPTIMIZING DRUG THERAPY IN DIABETIC NEPHROPATHY: A COMPREHENSIVE REVIEW
Abdul Balal Faizan Hassan Priyanshu Raj MD. Anees
Shivam Jha1, Ms. Ritu, Jeewanjot singh
Article Status
Available Documents
Abstract
Diabetic renal failure is a complex metabolic and renal pathology resulting from the interplay of hyperglycemia, hypertension, and chronic kidney disease (CKD). The management of this condition requires a comprehensive understanding of the pathophysiology, pharmacokinetic changes, and current clinical guidelines to ensure safe and effective pharmacotherapy. Renal impairment significantly alters drug absorption, distribution, metabolism, and excretion, necessitating careful dose adjustments to prevent toxicity and maintain therapeutic efficacy. The principles of dose modification involve estimating renal function using eGFR or creatinine clearance, classifying the degree of renal impairment, and applying strategies such as dose reduction, increased dosing interval, or a combination of both. The choice of antidiabetic agents should balance glycemic control and renal safety, with metformin, SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors being preferred options based on the stage of CKD. Insulin therapy requires individualized dosing and close monitoring to avoid hypoglycemia. Managing comorbidities such as hypertension, dyslipidemia, and cardiovascular risk is crucial, with RAAS inhibitors, statins, and antiplatelet agents being key components of the treatment plan. Clinical guidelines from ADA, KDIGO, and EASD provide evidence-based recommendations for personalized therapy, emphasizing the importance of multidisciplinary care, patient education, and regular monitoring of renal function and metabolic parameters. Future directions include the development of novel renoprotective agents, precision medicine approaches, and the integration of digital health technologies to optimize outcomes in this vulnerable patient population.
How to Cite this Paper
Balal, A., Hassan, F., Raj, P. & Anees, M. (2026). Optimizing Drug Therapy in Diabetic Nephropathy: A Comprehensive Review. International Journal of Creative and Open Research in Engineering and Management, <i>02</i>(04). https://doi.org/10.55041/ijcope.v2i4.408
Balal, Abdul, et al.. "Optimizing Drug Therapy in Diabetic Nephropathy: A Comprehensive Review." International Journal of Creative and Open Research in Engineering and Management, vol. 02, no. 04, 2026, pp. . doi:https://doi.org/10.55041/ijcope.v2i4.408.
Balal, Abdul,Faizan Hassan,Priyanshu Raj, and MD. Anees. "Optimizing Drug Therapy in Diabetic Nephropathy: A Comprehensive Review." International Journal of Creative and Open Research in Engineering and Management 02, no. 04 (2026). https://doi.org/https://doi.org/10.55041/ijcope.v2i4.408.
Search & Index
References
- Hanifah M, Harahap Y, Purwanto DJ. Determination of 5-Fluorouracil in Dried Blood Spots for Therapeutic Drug Monitoring and Adverse Event Assessment in Breast Cancer Patients. Clin Pharmacol Adv Appl. 2025;17:243–51.
- Kakar A, Kakar N, Durand A-C, Mouelhi Y, Gentile S. Global Impact of Obesity and Diabetes on the Increase Incidence and Prevalence of Chronic Kidney disease (CKD) and End Stage Renal Disease (ESRD): A Systematic Review. ResearchSquare. 2021;1–17.
- Ruiz A, DiCristina S. Absorption to Excretion: The Aging Body’s Take on Drugs – A Review of Pharmacokinetic Changes and their Impact on Medication Management. Curr Pharmacol Reports. 2025;11:1–13.
- Thakur AK, Tyagi S, Shekhar N. Comorbid brain disorders associated with diabetes: therapeutic potentials of prebiotics, probiotics and herbal drugs. Transl Med Commun. 2019;4:1–13.
- Susilawati E, Levita J, Susilawati Y, Sumiwi SA. Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients. Med Sci. 2023;11:1–12.
- Lou H, Jiang Y, Xu C, Dong ZM, Liu D, Qiao C, et al. Effects of a combination of dyslipidemia and hypertension on the glycemic control of patients with type 2 diabetes mellitus: a cross-sectional study. SAGE Open Med. 2024;12.
- Chu HY, Jain R, Xie H, Pottinger P, Fredricks DN. Voriconazole therapeutic drug monitoring: Retrospective cohort study of the relationship to clinical outcomes and adverse events. BMC Infect Dis. 2013;13:1–9.
- Lim CE, Pasternak B, Eliasson B, Ueda P. Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes. Diabetologia. 2025;68:1680–95.
- Guo L, Yuan J, Cai L, Zhu C, Zheng Y, Yang H, et al. Disease Burden of Gastrointestinal Tumors in China From 1990 to 2021, an Analysis for the Global Burden of Disease Study 2021. J Evid Based Med. 2025;
- Pereira F, Bolduc C, Melly P, Renggli V. Informal Caregivers in Transitional Hospital-to-Home Care for Older People: Addressing Gaps in Pre-Discharge Collaboration for Enhanced Patient Outcomes. Patient Prefer Adherence . 2025;19:3159–67.
Ethical Compliance & Review Process
- •All submissions are screened under plagiarism detection.
- •Review follows editorial policy.
- •Authors retain copyright.
- •Peer Review Type: Double-Blind Peer Review
- •Published on: Apr 17 2026
This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. You are free to share and adapt this work for non-commercial purposes with proper attribution.